UBS’s AIM ImmunoTech AIM Stock Holding History

UBS’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-1	Closed	-$15.4K	–	9411
2014 Q2	$12K	Hold	1	–	–	﹤0.01%	8757
2014 Q1	$12K	Buy	+1	New	+$21.2K	﹤0.01%	8768
2013 Q4	–	Hold	0	–	–	–	9995
2013 Q3	–	Hold	0	–	–	–	10111
2013 Q2	–	Hold	0	–	–	–	10255

Other funds holding AIM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

OAM

Occidental Asset Management Burlingame, California $844M AUM 20.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BTS

BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS's AIM Position: Q3 2014 in Review

UBS sold out of AIM ImmunoTech (AIM) in Q3 2014, closing a stake of 1 share — an estimated $15.4K sold.

UBS first reported a position in AIM in Q1 2014 and held it in 2 quarters. The position peaked at $12K in Q2 2014. 14 funds tracked by Wall St. Rank hold AIM as of Q3 2014.

UBS reported no remaining AIM ImmunoTech position as of Q3 2014 after selling out during the quarter.
UBS sold 1 AIM ImmunoTech share in Q3 2014, an estimated $15.4K.
UBS first reported a position in AIM ImmunoTech in Q1 2014 and held it in 2 quarters.
UBS's AIM ImmunoTech position peaked at $12K in Q2 2014.
14 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.